Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 3/2016

01-06-2016 | Review

Phosphate binders in chronic kidney disease: a systematic review of recent data

Author: Jürgen Floege

Published in: Journal of Nephrology | Issue 3/2016

Login to get access

Abstract

Hyperphosphatemia is common in chronic kidney disease (CKD) and is treated by dietary measures, dialysis techniques and/or phosphate binders. For the present review PubMed was searched for new publications on phosphate binders appearing between January 2010 and October 2015. This review summarizes the latest information on non-pharmacological measures and their problems in lowering phosphate in CKD patients, effects of phosphate binders on morbidity and mortality, adherence to phosphate binder therapy as well as new information on specific aspects of the various phosphate binders on the market: calcium acetate, calcium carbonate, magnesium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, aluminum-containing phosphate binders, and new compounds in development. The review also briefly covers the emerging field of drugs targeting intestinal phosphate transporters.
Literature
1.
Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312–1324PubMedCrossRef
2.
Mehrotra R, Peralta CA, Chen SC, Li S, Sachs M, Shah A, Norris K, Saab G, Whaley-Connell A, Kestenbaum B, McCullough PA, Kidney early evaluation program I (2013) No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int 84:989–997PubMedPubMedCentralCrossRef
3.
Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM (2011) Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109:697–711PubMedPubMedCentralCrossRef
4.
Abbasian N, Burton JO, Herbert KE, Tregunna BE, Brown JR, Ghaderi-Najafabadi M, Brunskill NJ, Goodall AH, Bevington A (2015) Hyperphosphatemia, phosphoprotein phosphatases, and microparticle release in vascular endothelial cells. J Am Soc Nephrol 26:2152–2162PubMedPubMedCentralCrossRef
5.
Shobeiri N, Adams MA, Holden RM (2014) Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol 77:39–54PubMedCrossRef
6.
Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913–921PubMedCrossRef
7.
Nagel CJ, Casal MC, Lindley E, Rogers S, Pancirova J, Kernc J, Copley JB, Fouque D (2014) Management of hyperphosphataemia: practices and perspectives amongst the renal care community. J Ren Care 40:230–238PubMedCrossRef
8.
Cupisti A, Benini O, Ferretti V, Gianfaldoni D, Kalantar-Zadeh K (2012) Novel differential measurement of natural and added phosphorus in cooked ham with or without preservatives. J Ren Nutr 22:533–540PubMedCrossRef
9.
Penne EL, van der Weerd NC, van den Dorpel MA, Grooteman MP, Levesque R, Nube MJ, Bots ML, Blankestijn PJ, ter Wee PM, Investigators C (2010) Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). Am J Kidney Dis 55:77–87PubMedCrossRef
10.
Kuhlmann MK (2010) Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 29:137–144PubMedCrossRef
11.
Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Kliger AS, Frequent Hemodialysis Network Trial G (2012) Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 23:727–738PubMedPubMedCentralCrossRef
12.
Movilli E, Camerini C, Gaggia P, Poiatti P, Pola A, Viola BF, Zubani R, Jeannin G, Cancarini G (2011) Effect of post-dilutional on-line haemodiafiltration on serum calcium, phosphate and parathyroid hormone concentrations in uraemic patients. Nephrol Dial Transpl 26:4032–4037CrossRef
13.
Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, Basile C, David S, Gazzanelli L, Tampieri G, Isola E, Marzolla O, Memoli B, Ganadu M, Reina E, Bertoli S, Ferrara R, Casu D, Logias F, Tarchini R, Mattana G, Passaghe M, Fundoni G, Villa G, Di Iorio BR, Pontoriero G, Zoccali C (2014) Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial. Nephrol Dial Transpl 29:1239–1246CrossRef
14.
Zitt E, Fouque D, Jacobson SH, Malberti F, Ryba M, Urena P, Rix M, Dehmel B, Manamley N, Vervloet M (2013) Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J 6:287–294PubMedPubMedCentralCrossRef
15.
Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB (2015) Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol ASN-2015020152 [Epub ahead of print]
16.
Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K (2010) Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 56:842–851PubMedPubMedCentralCrossRef
17.
Cannata-Andia JB, Fernandez-Martin JL, Locatelli F, London G, Gorriz JL, Floege J, Ketteler M, Ferreira A, Covic A, Rutkowski B, Memmos D, Bos WJ, Teplan V, Nagy J, Tielemans C, Verbeelen D, Goldsmith D, Kramar R, Martin PY, Wuthrich RP, Pavlovic D, Benedik M, Sanchez JE, Martinez-Camblor P, Naves-Diaz M, Carrero JJ, Zoccali C (2013) Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 84:998–1008PubMedCrossRef
18.
Lopes AA, Tong L, Thumma J, Li Y, Fuller DS, Morgenstern H, Bommer J, Kerr PG, Tentori F, Akiba T, Gillespie BW, Robinson BM, Port FK, Pisoni RL (2012) Phosphate binder use and mortality among hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 60:90–101PubMedPubMedCentralCrossRef
19.
20.
Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J (2015) Evaluation of cinacalcet HTtLCETI: cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132:27–39PubMedCrossRef
21.
Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407–1415PubMedPubMedCentralCrossRef
22.
Van Camp YP, Vrijens B, Abraham I, Van Rompaey B, Elseviers MM (2014) Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. J Nephrol 27(6):673–679
23.
Covic A, Rastogi A (2013) Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol 14:153PubMedPubMedCentralCrossRef
24.
Wileman V, Farrington K, Wellsted D, Almond M, Davenport A, Chilcot J (2015) Medication beliefs are associated with phosphate binder non-adherence in hyperphosphatemic haemodialysis patients. Br J Health Psychol 20:563–578PubMedCrossRef
25.
Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A (2010) Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol 23:525–534PubMed
26.
Fouque D, Horne R, Cozzolino M, Kalantar-Zadeh K (2014) Balancing nutrition and serum phosphorus in maintenance dialysis. Am J Kidney Dis 64:143–150PubMedCrossRef
27.
Shi YX, Fan XY, Han HJ, Wu QX, Di HJ, Hou YH, Zhao Y (2013) Effectiveness of a nurse-led intensive educational programme on chronic kidney failure patients with hyperphosphataemia: randomised controlled trial. J Clin Nurs 22:1189–1197PubMedCrossRef
28.
Van Camp YP, Huybrechts SA, Van Rompaey B, Elseviers MM (2012) Nurse-led education and counselling to enhance adherence to phosphate binders. J Clin Nurs 21:1304–1313PubMedCrossRef
29.
Umeukeje EM, Merighi JR, Browne T, Victoroff JN, Umanath K, Lewis JB, Ikizler TA, Wallston KA, Cavanaugh K (2015) Self-motivation is associated with phosphorus control in end-stage renal disease. J Ren Nutr 25:433–439PubMedPubMedCentralCrossRef
30.
Jamal SA, Moe SM (2012) Calcium builds strong bones, and more is better–correct? Well, maybe not. Clin J Am Soc Nephrol 7:1877–1883PubMedCrossRef
31.
West SL, Swan VJ, Jamal SA (2010) Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population. Clin J Am Soc Nephrol 5(Suppl 1):S41–S47PubMedCrossRef
32.
Winkelmayer WC, Liu J, Kestenbaum B (2011) Comparative effectiveness of calcium-containing phosphate binders in incident US dialysis patients. Clin J Am Soc Nephrol 6:175–183PubMedPubMedCentralCrossRef
33.
Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382:1268–1277PubMedCrossRef
34.
Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, Fouque D, investigators As (2011) Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 15:485–492PubMedCrossRef
35.
Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M (2013) Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int 83:959–966PubMedCrossRef
36.
Spiegel DM, Brady K (2012) Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 81:1116–1122PubMedPubMedCentralCrossRef
37.
Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM (2010) Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 21:103–112PubMedPubMedCentralCrossRef
38.
39.
de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J (2010) Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transpl 25:3707–3717CrossRef
40.
Evsanaa B, Liu I, Aliazardeh B, Mahdavi S, Bajwa G, Gula J, Tam M, Sze E, Roscoe JM, Tam PY, Sikaneta T (2015) MgCaCO3 versus CaCO3 in peritoneal dialysis patients—a cross-over pilot trial. Perit Dial Int 35:31–34PubMedPubMedCentralCrossRef
41.
Tzanakis IP, Stamataki EE, Papadaki AN, Giannakis N, Damianakis NE, Oreopoulos DG (2014) Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. Int Urol Nephrol 46:2199–2205PubMedCrossRef
42.
De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D’Haese PC, Neven E (2013) Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83:1109–1117PubMedPubMedCentralCrossRef
43.
Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A, Investigators IS (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62:771–778PubMedCrossRef
44.
Di Iorio B, Bellasi A, Russo D, Investigators IS (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 7:487–493PubMedCrossRef
45.
Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, Shikuma S, Ishigami J, Tajima M, Asai T, Okado T, Kuwahara M, Sasaki S, Tsukamoto Y (2012) Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol 16:930–937PubMedCrossRef
46.
Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72:1130–1137PubMedCrossRef
47.
Maizel J, Six I, Dupont S, Secq E, Dehedin B, Barreto FC, Benchitrit J, Poirot S, Slama M, Tribouilloy C, Choukroun G, Maziere JC, Drueke TB, Massy ZA (2013) Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. Kidney Int 84:491–500PubMedCrossRef
48.
Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A (2011) Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 57:422–431PubMedCrossRef
49.
Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, Edwards NC, Steeds RP, Ferro CJ (2013) Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24:842–852PubMedPubMedCentralCrossRef
50.
Di Lullo L, Floccari F, Santoboni A, Barbera V, Rivera RF, Granata A, Morrone L, Russo D (2013) Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol 26:739–744PubMedCrossRef
51.
Lin YF, Chien CT, Kan WC, Chen YM, Chu TS, Hung KY, Tsai TJ, Wu KD, Wu MS (2011) Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: a randomized, open-label, parallel-group study. Clin Drug Investig 31:257–267PubMedCrossRef
52.
Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Donate-Correa J, Cazana-Perez V, Garcia-Perez J (2011) Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 6:2272–2279
53.
Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE (2012) Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 7:934–942PubMedPubMedCentralCrossRef
54.
Guida B, Cataldi M, Riccio E, Grumetto L, Pota A, Borrelli S, Memoli A, Barbato F, Argentino G, Salerno G, Memoli B (2013) Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a cross-sectional observational study. PLoS One 8:e73558PubMedPubMedCentralCrossRef
55.
Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transpl 25:2672–2679CrossRef
56.
Takagi K, Masuda K, Yamazaki M, Kiyohara C, Itoh S, Wasaki M, Inoue H (2010) Metal ion and vitamin adsorption profiles of phosphate binder ion-exchange resins. Clin Nephrol 73:30–35PubMedCrossRef
57.
Pierce D, Hossack S, Poole L, Robinson A, Van Heusen H, Martin P, Smyth M (2011) The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transpl 26:1615–1621CrossRef
58.
Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, Guastamacchia E, Triggiani V (2014) Sevelamer carbonate markedly reduces levothyroxine absorption. Endocr Metab Immune Disord Drug Targets 14:206–209PubMedCrossRef
59.
Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S (2010) A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Am J Kidney Dis 55:307–315PubMedCrossRef
60.
Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, Joao-Luiz MV, Degaspari S, Scavone C, Kawamoto E (2014) Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Int J Immunopathol Pharmacol 27:25–35PubMedCrossRef
61.
Ito K, Takeshima A, Shishido K, Wakasa M, Kumata C, Matsuzaka K, Nakajima Y, Ogata H (2014) Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. Ther Apher Dial 18(Suppl 2):19–23PubMedCrossRef
62.
Locatelli F, Dimkovic N, Spasovski G (2014) Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients. Expert Opin Pharmacother 15:1475–1488PubMedCrossRef
63.
Locatelli F, Dimkovic N, Pontoriero G, Spasovski G, Pljesa S, Kostic S, Manning A, Sano H, Nakajima S (2010) Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transpl 25:574–581CrossRef
64.
Locatelli F, Dimkovic N, Spasovski G (2013) Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transpl 28:1874–1888CrossRef
65.
Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G (2014) The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study. Nephrol Dial Transpl 29:1061–1073CrossRef
66.
Hertel J, Locatelli F, Spasovski G, Dimkovic N, Wanner C (2015) Randomized, double-blind, placebo-controlled, withdrawal study of colestilan after dose titration in chronic kidney disease dialysis patients with hyperphosphatemia. Nephron 130:229–238PubMedCrossRef
67.
Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, Group AG-lS (2015) Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol 10:759–766PubMedPubMedCentralCrossRef
68.
Vemuri N, Michelis MF, Matalon A (2011) Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study. BMC Nephrol 12:49PubMedPubMedCentralCrossRef
69.
Dellanna F, Reichel H, Seibt F (2012) Efficacy and safety of lanthanum carbonate in German patients on dialysis. Clin Nephrol 78:382–390PubMedCrossRef
70.
Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M (2015) Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transpl 30:107–114CrossRef
71.
Arenas MD, Rebollo P, Malek T, Moledous A, Gil MT, Alvarez-Ude F, Morales A, Cotilla E (2010) A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol 23:683–692PubMed
72.
Takahara Y, Matsuda Y, Takahashi S, Shigematsu T (2014) Lanthanum carbonate study G: efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol 82:181–190PubMedCrossRef
73.
Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transpl 26:2567–2571CrossRef
74.
Urena-Torres P, Prie D, Keddad K, Preston P, Wilde P, Wan H, Copley JB (2014) Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrol 15:71PubMedPubMedCentralCrossRef
75.
Zhang C, Wen J, Li Z, Fan J (2013) Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 14:226PubMedPubMedCentralCrossRef
76.
Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drueke TB, Massy ZA (2012) Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transpl 27:505–513
77.
Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K (2012) Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study. Clin Nephrol 78:216–223PubMedCrossRef
78.
Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S (2013) Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharmacol Ther 18:439–446PubMedCrossRef
79.
Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology (Carlton) 16:290–298CrossRef
80.
Shigematsu T, Tokumoto A, Nakaoka A, Arisaka H (2011) Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial 15:176–184PubMedCrossRef
81.
Di Iorio B, Cucciniello E (2010) Lanthanum carbonate is not associated with QT interval modification in hemodialysis patients. Clin Pharmacol 2:89–93PubMedPubMedCentral
82.
Hutchison AJ, Barnett ME, Krause R, Siami GA, Lanthanum Carbonate Study G (2009) Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease stage 5 receiving hemodialysis. Clin Nephrol 71:286–295PubMed
83.
84.
Hara S, Fujimori A, Nishi S (2015) Clinicopathological characteristics of lanthanum deposition in the gastrointestinal tract of dialysis patients (abstract). J Am Soc Nephrol 26:279A
85.
Valika AH, Jain D, Jaffe PE, Moeckel G, Brewster UC (2016) A nodular foreign body reaction in a dialysis patient receiving long-term treatment with lanthanum carbonate. Am J Kidney Dis 67(1):128–32
86.
Black T, Philips G, Burbridge R (2013) Pharmacobezoar in a patient on an oral phosphate binder. Gastrointest Endosc 77:511–512PubMedCrossRef
87.
How PP, Anattiwong P, Mason DL, Arruda JA, Lau AH (2011) Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients. Hemodial Int 15:95–99PubMedCrossRef
88.
Pierce D, Hossack S, Robinson A, Zhang P, Martin P (2012) Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects. Clin Ther 34(1290–300):e2
89.
Hayashi H, Machida M, Sekine T, Yamaguchi H, Kiriyama T, Kumita S (2010) Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis. Jpn J Radiol 28:322–324PubMedCrossRef
90.
Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3–5. Am J Kidney Dis 65:728–736PubMedCrossRef
91.
Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9:543–552PubMedPubMedCentralCrossRef
92.
Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study G (2015) Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26:493–503PubMedCrossRef
93.
Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study G (2015) Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol 26:2578–2587PubMedPubMedCentralCrossRef
94.
Lee CT, Wu IW, Chiang SS, Peng YS, Shu KH, Wu MJ, Wu MS (2015) Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. J Nephrol 28:105–113PubMedCrossRef
95.
Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y (2012) Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 36:478–487PubMedCrossRef
96.
Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H (2014) A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transpl 29:1053–1060CrossRef
97.
Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study G (2013) Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 61:759–766PubMedCrossRef
98.
Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study G (2015) The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis 66:479–488PubMedPubMedCentralCrossRef
99.
Cozzolino M, Funk F, Rakov V, Phan O, Teitelbaum I (2014) Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide. Curr Drug Metab 15:953–965PubMedPubMedCentralCrossRef
100.
Chong E, Kalia V, Willsie S, Winkle P (2014) Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. J Nephrol 27(6):659–666
101.
Phan O, Maillard M, Funk F, Stehle JC, Burnier M (2015) 1d.08: effect of Pa21, a new iron-based phosphate binder on fibroblast growth factor 23 (Fgf23) and vascular calcifications in uremic rats. J Hypertens 33(Suppl 1):e16–e17PubMedCrossRef
102.
Wuthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA (2013) Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 8:280–289PubMedCrossRef
103.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Group PAS (2014) A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int 86:638–647CrossRef
104.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study G (2015) Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transpl 30:1037–1046CrossRef
105.
Mudge DW, Johnson DW, Hawley CM, Campbell SB, Isbel NM, van Eps CL, Petrie JJ (2011) Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 12:20PubMedPubMedCentralCrossRef
106.
Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC (2013) Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract 123:93–101PubMedCrossRef
107.
Savica V, Calo LA, Monardo P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G (2009) Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 20:639–644PubMedPubMedCentralCrossRef
108.
Akizawa T, Tsuruta Y, Okada Y, Miyauchi Y, Suda A, Kasahara H, Sasaki N, Maeda Y, Suzuki T, Matsui N, Niwayama J, Suzuki T, Hara H, Asano Y, Komemushi S, Fukagawa M (2014) Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol 15:98PubMedPubMedCentralCrossRef
109.
110.
Nakaki J, Yamaguchi S, Torii Y, Inoue A, Minakami S, Kanno T, Murakami M, Tsuzuki M, Mochizuki H, Suyama K, Miyamoto M (2013) Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer. Eur J Pharmacol 714:312–317PubMedCrossRef
111.
Moustafa M, Lehrner L, Al-Saghir F, Smith M, Goyal S, Dillon M, Hunter J, Holmes-Farley R (2014) A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis. Int J Nephrol Renovasc Dis 7:141–152PubMedPubMedCentral
112.
Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ (2010) Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 77:897–903PubMedCrossRef
113.
Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, Balfour A, Junge G, Akiba T, Fukagawa M (2011) Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: a 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology (Carlton) 16:743–750CrossRef
114.
Gschwind HP, Schmid DG, von Blanckenburg F, Oelze M, van Zuilen K, Slade AJ, Stitah S, Kaufmann D, Swart P (2014) Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope (58)Fe. Metallomics 6:2062–2071PubMedCrossRef
115.
Tamagawa K, Nakayama-Imaohji H, Wakimoto S, Ichimura M, Kuwahara T (2010) Utilization of titanium oxide-like compound as an inorganic phosphate adsorbent for the control of serum phosphate level in chronic renal failure. J Med Invest 57:275–283PubMedCrossRef
116.
Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J, Ryan S, Phillips L, Liu S, Arbeeny C, Ledbetter S, Sabbagh Y (2012) Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 23:1691–1700PubMedPubMedCentralCrossRef
117.
Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG (2010) Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 5:582–589PubMedPubMedCentralCrossRef
118.
Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW (2008) A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131–1138PubMedPubMedCentralCrossRef
119.
El Borolossy R, El Wakeel LM, El Hakim I, Sabri N (2016) Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol 31(2):289–296
120.
Pelletier S, Roth H, Bouchet JL, Drueke T, London G, Fouque D, French P, Calcium Observatory i (2010) Mineral and bone disease pattern in elderly haemodialysis patients. Nephrol Dial Transpl 25:3062–3070CrossRef
121.
Tamura MK, Tan JC, O’Hare AM (2012) Optimizing renal replacement therapy in older adults: a framework for making individualized decisions. Kidney Int 82:261–269PubMedCrossRef
Metadata
Title
Phosphate binders in chronic kidney disease: a systematic review of recent data
Author
Jürgen Floege
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 3/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-016-0266-9

Other articles of this Issue 3/2016

Journal of Nephrology 3/2016 Go to the issue

Original Article

Assessment of the geriatric competence and perceived needs of Italian nephrologists: an internet survey

Original Article

Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis

Erratum

Erratum to: Podocyturia is significantly elevated in untreated vs treated Fabry adult patients

Position Papers and Guidelines

A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy

Original Article

Hospital-acquired acute kidney injury: an analysis of baseline estimated glomerular filtration rate and in-hospital mortality

Original Article

Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits